PARIS–(BUSINESS WIRE)–Genethon currently is developing a drug candidate that has demonstrated its efficacy in the first patients to be treated for Duchenne.
Home › RSS › Marking World Duchenne Muscular Dystrophy Day, Genethon Reaffirms Its Commitment to Helping Patients for 35 Years and Provides an Update on Its Promising Gene Therapy Drug Candidate for This Fatal Disease